SEC Form 4 · accession 0001209191-17-022934
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Conway
Director
Period of report
Mar 24, 2017
Accepted (ET)
Mar 27, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 24, 2017 | P | 25,000 | $2.59 | A | 25,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.52 to $2.75. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price